Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Escitalopram
Drug ID BADD_D00809
Description Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram].[A185420] It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class.[A185726] Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822]
Indications and Usage Escitalopram is indicated for both acute and maintenance treatment of major depressive disorder (MDD) and for the acute treatment of generalized anxiety disorder (GAD).[L8513] It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.[L8516]
Marketing Status approved
ATC Code N06AB10
DrugBank ID DB01175
KEGG ID D07913
MeSH ID D000089983
PubChem ID 146570
TTD Drug ID D08RBC
NDC Product Code 80425-0320; 50090-4915; 51655-284; 53002-1431; 67296-1200; 0456-2010; 0456-2020; 69097-848; 70518-1785; 71335-1030; 0615-8366; 42708-163; 45865-699; 55700-847; 69844-079; 72189-424; 72189-451; 16729-168; 43547-281; 43547-282; 61919-652; 63187-281; 68001-456; 68071-5248; 68788-7461; 69844-077; 70934-630; 68001-454; 68071-2035; 68645-520; 68788-7510; 69844-078; 70934-957; 71205-344; 71610-425; 71610-534; 72189-449; 16571-755; 16729-170; 50090-2196; 51655-236; 53002-2438; 60760-393; 68788-7912; 70518-2317; 70771-1145; 71335-1002; 71335-1187; 71335-1307; 16571-757; 51655-766; 54838-551; 70518-2430; 70771-1147; 50090-4363; 50090-5312; 50090-6534; 51655-116; 51655-149; 69097-847; 69097-849; 70518-1876; 71205-325; 76282-250; 76282-251; 42708-155; 50090-1930; 70518-2472; 70518-3151; 70771-1146; 82982-030; 43547-280; 50090-6190; 51655-277; 55700-818; 63187-217; 67296-1597; 68001-455; 68645-519; 0456-2005; 70518-1805; 70518-2597; 71335-1571; 72189-438; 0615-8365; 72789-194; 76282-249; 16571-756; 33342-053; 60760-170; 65162-705; 71205-782; 71335-1241; 71335-2058; 0615-8348; 16729-169; 43063-661
UNII 4O4S742ANY
Synonyms Escitalopram | Escitalopram Oxalate | Lexapro
Chemical Information
Molecular Formula C20H21FN2O
CAS Registry Number 128196-01-0
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Facial paresis17.04.03.002--
Large intestine polyp16.05.02.006; 07.20.01.010--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Necrotising colitis07.08.01.0130.000028%Not Available
Metabolic syndrome14.06.02.007; 05.06.02.007; 24.08.02.0140.000019%Not Available
Latent tetany14.04.01.015; 17.05.03.012; 15.05.03.027--Not Available
Haemodynamic instability24.03.02.0060.000076%Not Available
Eye pruritus06.04.05.006--Not Available
Respiratory tract congestion22.02.07.0030.000019%Not Available
Lymphatic disorder01.09.01.003--Not Available
Nasal discomfort22.12.03.0120.000061%Not Available
Orgasmic sensation decreased19.08.01.003; 21.03.02.0080.000019%Not Available
Musculoskeletal stiffness15.03.05.0270.000127%Not Available
Epigastric discomfort07.01.02.004--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Bronchitis viral22.07.05.003; 11.05.04.015--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.000322%Not Available
Clonic convulsion17.12.03.008--Not Available
Injection site swelling12.07.03.018; 08.02.03.0170.000106%Not Available
Infusion site pain12.07.05.002; 08.02.05.014--Not Available
Tracheal disorder22.04.07.005--Not Available
Thermal burn23.03.11.042; 12.05.04.001--
Growth retardation15.03.05.016; 14.03.02.031; 05.03.02.0070.000038%
Cerebral haematoma24.07.04.006; 17.08.01.0140.000066%Not Available
Depressive symptom19.15.02.0030.000163%Not Available
Affect lability19.04.01.001--Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.000051%Not Available
Cerebral disorder17.02.10.0170.000019%Not Available
Necrotising enterocolitis neonatal07.08.03.011; 18.04.11.0020.000019%Not Available
Foetal death18.01.02.003; 08.04.01.0110.000104%
The 28th Page    First    Pre   28 29 30 31 32    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene